Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (1,310,295)	$ (2,111,860)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	349,691	207,306
Loss on derivative liability	55,000	450,000
Loss (gain) on forgiveness of debt	(27,628)
Depreciation and amortization	529,486	437,720
Changes in operating assets and liabilities
Accounts receivable	(1,850,375)	2,846
Accrued interest - loans payable related party	(25,000)	427,482
Accrued interest - loans payable third party	16,300	16,300
Other current assets	(14,837)	179
Accounts payable and accrued expenses	3,024,181	191,392
Net cash provided by/(used in) operating activities	746,523	(378,635)
Cash flows from investing activities:
Purchase of patents	(75,000)	(20,000)
Net cash used in investing activities	(75,000)	(20,000)
Cash flows from financing activities:
Proceeds from loans		250,000
Repayment of purchase price of patents	(155,614)
Loan payable - third party	(16,000)
Proceeds/(repayment) from sale of future revenues	(129,622)	150,000
Net cash from/(used in) financing activities	(301,236)	400,000
Net increase (decrease) in cash and cash equivalents	370,287	1,365
Cash and cash equivalents at beginning of year	166,911	165,546
Cash and cash equivalents at end of year	537,198	166,911
Non Cash Investing and Financing Activities
Accounts payable for patent purchase, net of imputed interest of $336,781 and $0, respectively	1,238,219
Supplemental disclosure of cash flow information
Income taxes, including foreign taxing authorities withheld taxes of $5,000 and $1,039,900 during the years ended December 31, 2019, and 2018 respectively.	5,234	1,040,134
Interest	$ 467,280